Pathfinder Cell Therapy, Inc.
PFND · OTC
9/30/2015 | 6/30/2015 | 3/31/2015 | 12/31/2014 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.07 | 0.12 | 0.11 | -0.02 |
| FCF Yield | -3.34% | -3.42% | -7.13% | -23.79% |
| EV / EBITDA | -51.66 | -56.64 | -37.45 | -25.19 |
| Quality | ||||
| ROIC | 20.26% | 16.08% | 24.15% | 28.52% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.62 | 0.44 | 0.64 | 0.43 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -81.63% | 44.32% | -38.58% | 44.30% |
| Safety | ||||
| Net Debt / EBITDA | -26.00 | -36.58 | -25.29 | -22.74 |
| Interest Coverage | -2.61 | -1.85 | -2.83 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |